Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Esophagus
Published in: Esophagus 2/2012

01-06-2012 | Case Report

Endoscopic removal of a large hyperplastic (inflammatory) polyp in esophagogastric anastomosis after esophagectomy

Authors: Takeshi Matsutani, Koji Sasajima, Hiroshi Maruyama, Hiroshi Yoshida, Hironori Katayama, Masaru Hosone, Akihisa Matsuda, Eiji Uchida

Published in: Esophagus | Issue 2/2012

Login to get access

Abstract

Hyperplastic (inflammatory) polyp (HP) is uncommon in the esophagus and esophagogastric junction. We report a case of HP arising in the esophagogastric anastomosis 2 years after esophagectomy for esophageal squamous cell carcinoma in a 64-year-old woman. The lesion was resected endoscopically. The histopathological diagnosis was HP. There has been no evidence of carcinoma or HP for more than 6 years after initial surgery. This is the first reported case of HP arising in an esophagogastric anastomosis after esophageal surgery that was successfully treated by endoscopic resection.
Literature
1.
Abraham SC, Singh VK, Yardley JH, Wu TT. Hyperplastic polyps of the esophagus and esophagogastric junction: histologic and clinicopathologic findings. Am J Surg Pathol. 2001;25:1180–7.PubMedCrossRef
2.
Abraham SC, Singh VK, Yardley JH, Wu TT. Hyperplastic polyps of the stomach: associations with histologic patterns of gastritis and gastric atrophy. Am J Surg Pathol. 2001;25:500–7.PubMedCrossRef
3.
Long KB, Odze RD. Gastroesophageal junction hyperplastic (inflammatory) polyps: a clinical and pathologic study of 46 cases. Am J Surg Pathol. 2011;35:1038–44.PubMedCrossRef
4.
Hongo M, Fujimoto K. Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long-term proton pump inhibitor therapy: a prospective study in Japan. J Gastroenterol. 2010;45:618–24.PubMedCrossRef
5.
Marie I, Ducrotte P, Denis P, Hellot MF, Levesque H. Oesophageal mucosal involvement in patients with systemic sclerosis receiving proton pump inhibitor therapy. Aliment Pharmacol Ther. 2006;24:1593–601.PubMedCrossRef
6.
Bleshman MH, Banner MP, Johnson RC, DeFord JW. The inflammatory esophagogastric polyp and fold. Radiology. 1978;128:589–93.PubMed
7.
Yamane T, Uchiyama K, Ishii T, Ishii H, Takizawa R, Omura M, et al. Case of inflammatory fibroid polyp of the esophagogastric junction. Dig Endosc. 2009;21:97–100.PubMedCrossRef
8.
Daibo M, Itabashi M, Hirota T. Malignant transformation of gastric hyperplastic polyps. Am J Gastroenterol. 1987;82:1016–25.PubMed
9.
Dijkhuizen SM, Entius MM, Clement MJ, Polak MM, Van den Berg FM, Craanen ME, et al. Multiple hyperplastic polyps in the stomach: evidence for clonality and neoplastic potential. Gastroenterology. 1997;112:561–6.PubMedCrossRef
10.
Glassman M, Bostwick HE, Godine L, Newman LJ. Endoscopic removal of inflammatory esophagogastric polyps in children. J Pediatr Gastroenterol Nutr. 1991;13:110–4.PubMedCrossRef
11.
Styles RA, Gibb SP, Tarshis A, Silverman ML, Scholz FJ. Esophagogastric polyps: radiographic and endoscopic findings. Radiology. 1985;154:307–11.PubMed
12.
Adachi K, Fujishiro H, Katsube T, Yuki M, Ono M, Kawamura A, et al. Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. J Gastroenterol Hepatol. 2001;16:1191–6.PubMedCrossRef
13.
Rice TW, Goldblum JR, Rybicki LA, Rajeswaran J, Murthy SC, Mason DP, et al. Fate of the esophagogastric anastomosis. J Thorac Cardiovasc Surg. 2011;141:875–80, 80 e1.
14.
De Ceglie A, Lapertosa G, Blanchi S, Di Muzio M, Picasso M, Filiberti R, et al. Endoscopic mucosal resection of large hyperplastic polyps in 3 patients with Barrett’s esophagus. World J Gastroenterol. 2006;12:5699–704.PubMed
15.
Metadata
Title
Endoscopic removal of a large hyperplastic (inflammatory) polyp in esophagogastric anastomosis after esophagectomy
Authors
Takeshi Matsutani
Koji Sasajima
Hiroshi Maruyama
Hiroshi Yoshida
Hironori Katayama
Masaru Hosone
Akihisa Matsuda
Eiji Uchida
Publication date
01-06-2012
Publisher
Springer Japan
Published in
Esophagus / Issue 2/2012
Print ISSN: 1612-9059
Electronic ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-012-0310-3

Other articles of this Issue 2/2012

Esophagus 2/2012 Go to the issue

Editorial

Message from the Editor-in-Chief

Congress Report: President's Lecture

Radiotherapy for esophageal cancer in Japan

Original Article

Efficacy and safety of docetaxel/cisplatin/5-fluorouracil preoperative combination chemotherapy in esophageal cancer patients with extended lymph node metastases

Case Atlas

Treatment for esophageal malignant tumor without squamous cell carcinoma

Special Article

Comprehensive Registry of Esophageal Cancer in Japan, 2004

Erratum

Erratum to: Phase I clinical trial of vaccination with URLC10-derived peptide for patients with advanced esophageal cancer
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits